Reported results
- License and collaboration revenue was $274.4 million for the third quarter of 2026, compared to $4.7 million for the third quarter of 2025.
- Research and development expense was $41.3 million for the third quarter of 2026, compared to $40.0 million for the third quarter of 2025.
- General and administrative expense was $13.7 million for the third quarter of 2026, compared to $11.1 million for the third quarter of 2025.
- Net income was $220.0 million, or $3.07 per diluted share, for the third quarter of 2026, compared to a net loss of $39.3 million, or $0.62 per diluted share, for the third quarter of 2025.
- Cash, cash equivalents and marketable securities totaled $834.6 million as of September 30, 2026, compared to $646.0 million as of December 31, 2025.
Guidance
- The Company expects R&D expenses to increase for the remainder of the year as compared to the prior quarters in 2026.
Price and volatility reaction
The stock moved -2.4% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -19.7 vol points across the event (constant-maturity series — not the front-week crush).
| Measure | Value | Basis |
|---|---|---|
| Close before release | 135.26 | 2026-11-05 |
| Close after release | 132.04 | 2026-11-06 |
| Realised move | -2.4% | close to close |
| 30d ATM IV change | -19.7 vol pts | constant-maturity series, not the front expiry |
Source
The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.
